Conventional protocols for adult and pediatric tuberculosis (TB) diagnosis and treatment monitoring rely heavily on time-consuming bacterial culture or unquantifiable DNA detection methods for the presence of small numbers of bacteria. For pediatric TB, diagnosis and treatment are particularly difficult because current clinical protocols demand much from these young patients. Although they comprise a small percentage of the health care caseload, children who are co-infected with human immunodeficiency virus (HIV) and TB represent one of the most vulnerable groups with one of the highest mortality rates. We choose this challenging cohort (provided by a NIAID-sponsored clinical trial) to push the boundaries of what our technology platform can do. In order to address the current limitations in clinical management of pediatric TB, we have developed a rapid and quantitative diagnostic and monitoring platform for active TB wherein porous silicon nanodisks (referred to as pSiND), loaded with target biomarkers, are used for identification of disease signatures by a bench-top mass spectrometry (MS). Using this new biomarkers detection modality, pSiND-MS, we could detect and quantify two TB-specific blood-born biomarkers (CFP-10 and ESAT-6) at extremely low concentrations (1.0 fmol), which serve as signs of bacterial infection in advance of physiological manifestations observable by conventional protocols. Characteristics of ESAT-6 and CFP-10, i.e., antigens secreted by actively proliferating Mycobacterium tuberculosis (Mtb), make them ideal biomarkers for active TB diagnosis and candidates for TB vaccine development. We used this approach to distinguish adult patients with active TB from those with latent tuberculosis infection, or healthy volunteers. Also, based on multiplex detection and quantification by pSiND- MS, we differentiated pediatric TB-infected patients (n=36) from non-TB children (n=35) according to the peptidic patterns of CFP-10 and ESAT-6. Our categorization of patient samples matched clinical designations at 100% specificity and 94.4% sensitivity. Just as important, we could render accurate diagnoses within one hour of sample-to-answer processing rather than wait the typical 4-6 weeks. In this proposal, we aim to: 1) design and develop the scale-up nanodisk microfabrication protocol with FDA compliant in cGMP facilities; 2) conduct an extensive clinical validation of pSiND-MS using samples from a large cohort of children with HIV/TB; 3) determine effectiveness of our approach for rapid evaluation of treatment efficacy; and 4) optimize development and clinical validation of a portable pSiDN-miniMS system for identification and quantification of CFP-10 and ESAT-6. The pSiND-MS technology platform has an added advantage in that high-throughput and accurate mass spectrometry has become a virtually essential technology for clinical diagnosis in many parts of the world. The miniaturized and easy-to-use MS system at a shoebox size for point-of-care applications is aimed at serving patients in resource-limited areas. Achievement of all of our aims will significantly improve clinical management strategies for global TB control.

Public Health Relevance

Clinical diagnosis of TB disease in the highly vulnerable HIV-infected children is extremely challenging given the paucibacillary (few bacteria) nature of the disease and difficulties in obtaining relevant specimens. In this project, we implement a rapid nano-sensing and monitoring platform that combines the sophistication of mass- produced porous nanodisk fabrication, peptide-enrichment, and the powerful capabilities of bench-top MALDI mass spectrometry (MS) and/or a portable MS system specially developed for resource-limited area -- for detection and quantification of two TB-specific biomarkers (CFP-10 and ESAT-6) in patients' blood. Based on our preliminary studies, we are confident that this high-impact strategy could decrease the likelihood of disease progression, improve therapeutic regimens, and prevent the emergence of severe drug resistance strains.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI122932-02
Application #
9374400
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Miller, Judith A
Project Start
2016-03-10
Project End
2021-02-28
Budget Start
2016-11-01
Budget End
2017-02-28
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Arizona State University-Tempe Campus
Department
Miscellaneous
Type
Organized Research Units
DUNS #
943360412
City
Tempe
State
AZ
Country
United States
Zip Code
85287
Pu, Fan; Chiang, Spencer; Zhang, Wenpeng et al. (2018) Direct sampling mass spectrometry for clinical analysis. Analyst :
Sun, Dali; Hu, Tony Y (2018) A low cost mobile phone dark-field microscope for nanoparticle-based quantitative studies. Biosens Bioelectron 99:513-518
Liu, Chang; Lyon, Christopher J; Bu, Yang et al. (2018) Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. Clin Chem 64:791-800
Ren, Yue; Zhang, Wenpeng; Lin, Ziqing et al. (2018) In-capillary microextraction for direct mass spectrometry analysis of biological samples. Talanta 189:451-457
Zhang, Wei; Shu, Qingbo; Zhao, Zhen et al. (2018) Antigen 85B peptidomic analysis allows species-specific mycobacterial identification. Clin Proteomics 15:1
Chiang, Spencer; Zhang, Wenpeng; Ouyang, Zheng (2018) Paper spray ionization mass spectrometry: recent advances and clinical applications. Expert Rev Proteomics 15:781-789
Wu, Boyue; Ouyang, Zhengyu; Lyon, Christopher J et al. (2017) Plasma Levels of Complement Factor I and C4b Peptides Are Associated with HIV Suppression. ACS Infect Dis 3:880-885
Fan, Jia; Zhang, Hedong; Nguyen, Duc T et al. (2017) Rapid diagnosis of new and relapse tuberculosis by quantification of a circulating antigen in HIV-infected adults in the Greater Houston metropolitan area. BMC Med 15:188
Liang, Kai; Liu, Fei; Fan, Jia et al. (2017) Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng 1:
Liu, Chang; Zhao, Zhen; Fan, Jia et al. (2017) Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci U S A 114:3969-3974

Showing the most recent 10 out of 17 publications